Immunovant
IMVT | NASDAQ
$33.28
-$0.90 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$33.28
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Immunovant Company Profile
Company profile explainedCompany Profile
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Key Executives
| Name | Position |
|---|---|
| Eric Venker | Chief Executive Officer & Director |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary |
| Jay S. Stout | Chief Technology Officer |
| Melanie Gloria | Chief Operating Officer |
| Tiago Girao | Chief Financial Officer |
| Becky Merlina | Senior VP & Global Head of Quality |
| Christine Blodgett | Senior Vice President of Human Resources |
| Frank Torti | Executive Chairperson of the Board |
| Sheetal Patel | Senior Vice President of Clinical Development |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management |
Immunovant
| Country | United States |
| IPO Date | Jun 21, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Eric Venker |
Contact Details
1000 Park Forty Plaza Durham,
New York 27713 United States
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| SIC Code | 2836 |
Recent News
- 5 days ago / zacks.comDoes Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
- 5 days ago / seekingalpha.comDon't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
- 5 days ago / zacks.comImmunovant (IMVT) Upgraded to Buy: Here's What You Should Know
- 7 days ago / seekingalpha.comImmunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
- 8 days ago / benzinga.comImmunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
- 8 days ago / marketbeat.comWhat Immunovant (IMVT) Said on Its Q2 Earnings Call
- 8 days ago / globenewswire.comImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
- 8 days ago / globenewswire.comRoivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
- 27 days ago / globenewswire.comImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- 1 month ago / gurufocus.comKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Add to Watchlist
Select watchlists to add or remove IMVT